A Phase IIa safety study of topical R-flurbiprofen in patients with a history of non-melanoma skin cancer
Phase 2
Completed
- Conditions
- on-melanoma skin cancerNon-melanoma skin cancerCancer - Non melanoma skin cancer
- Registration Number
- ACTRN12606000192583
- Lead Sponsor
- PharmaQest Pty Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Must have had at least one non-melanoma skin cancer in the past 5 years.
Exclusion Criteria
Any significant medical disorder;Current use of NSAIDs (and unwilling to cease use).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method This is a safety and tolerability trial of a topically-applied gel. The primary outcome will be skin irritation at the sites of administration.[Assessments will be conducted after 1, 2 and 4 weeks of application.]
- Secondary Outcome Measures
Name Time Method Adverse events [Assessed throughout the trial];Systemic absorption of R-flurbiprofen[Assessed at weeks 2 and 4.]